Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb, Open-Label, Controlled, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine

NCT01345721 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT01345721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01345721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb, Open-Label, Controlled, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine
Lead sponsor
Novartis Vaccines
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2011
Completion date
September 30, 2011
Enrollment
205 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

meningococcal disease